Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Exelixis Inc EXEL

Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.


NDAQ:EXEL - Post by User

Bullboard Posts
Post by Oldmannorthon Oct 09, 2007 8:59am
1095 Views
Post# 13539709

Venture Exchange News

Venture Exchange Newshttps://www.tsx.com/en/news_events/news_releases/10-5-2007_TSXVenture-NewListingELE.html EXCELSIOR ENERGY LIMITED ("ELE") BULLETIN TYPE: New Listing-Shares BULLETIN DATE: October 5, 2007 TSX Venture Tier 2 Company Effective at the opening on Tuesday, October 9, 2007, the common shares of the Company will commence trading on TSX Venture Exchange. Pursuant to this listing, a total of 6,079,268 common shares of the Company are subject to a Tier 2 Value Escrow Agreement. The Company is classified as an 'oil and gas exploration and development' company. For further information, please refer to the Company's Filing Statement dated September 28, 2007 and filed on SEDAR on September 28, 2007. The Company is currently trading on CNQ. Corporate Jurisdiction: Alberta Capitalization: Unlimited common shares with no par value of which 95,307,708 common shares are issued and outstanding Escrowed Shares: 22,393,294 common shares Transfer Agent: Computershare Trust Company of Canada Trading Symbol: ELE CUSIP Number: 300750 10 6 Company Contact: Mary Kennedy. Vice-President Finance and Chief Financial Officer Company Address: 1510, 734 - 7th Avenue SW Calgary, Alberta T2P 3P8 Company Phone Number: (403) 537-1015 Company Fax Number: (403) 537-1021 Page Last Updated: October 5, 2007 TSX Venture Exchange
Bullboard Posts